

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

## **ANNOUNCEMENT ON ESTIMATED GROWTH IN RESULTS FOR THE FIRST THREE QUARTERS OF 2022**

This announcement is made by JOINN Laboratories (China) Co., Ltd. (the “**Company**”) pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Hong Kong Listing Rules.

### **IMPORTANT NOTICE:**

1. From January to September 2022, the net profit attributable to the shareholders of the Company (RMB607.2325 million to RMB656.8338 million) will increase by approximately RMB359.2264 million to RMB408.8276 million, representing a period-on-period increase of approximately 144.8% to 164.8% as compared with the data in the financial statements for the corresponding period of last year;
2. The net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses will increase by approximately RMB366.4033 million to RMB409.8683 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 168.6% to 188.6%. The net profits attributable to shareholders of the Company after deducting non-recurring profit and loss will record a period-on-period increase of approximately 61.0% to 81.0% as compared with the data in the financial statements for the corresponding period of last year, after excluding the unrealized gain from the fair value change of biological assets, interest income and the effects of exchange gains and losses.

## **I. ESTIMATED RESULTS FOR THE PERIOD**

### **(I) Period of estimated results**

From 1 January 2022 to 30 September 2022.

### **(II) Estimated results**

The preliminary estimates made by the Company's finance department are as follows:

1. It is expected that the net profit attributable to the shareholders of the Company for the period from January to September 2022 will increase from approximately RMB359.2264 million to RMB408.8276 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 144.8% to 164.8%.
2. It is expected that the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses for the period from January to September 2022 will increase by approximately RMB366.4033 million to RMB409.8683 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 168.6% to 188.6%. The net profits attributable to shareholders of the Company after deducting non-recurring profit and loss will record a period-on-period increase of approximately 61.0% to 81.0% as compared with the data in the financial statements for the corresponding period of last year, after excluding the unrealized gain from the fair value change of biological assets, interest income and the effects of exchange gains and losses.

(III) The estimated results have not been audited by certified public accountants.

## **II. RESULTS FOR THE CORRESPONDING PERIOD OF LAST YEAR**

Net profit attributable to shareholders of the Company for the corresponding period of last year: RMB248.0062 million. Net profit attributable to shareholders of the Company after deducting non-recurring profit or loss: RMB217.3254 million; earnings per share: RMB0.95.

## **III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS DURING THE PERIOD**

- (I) The financial results increment was mainly attributable to the following factors: (i) the Company has strengthened technological innovation and continues to strengthen its research and development support for innovative drugs, gaining the trust of innovative research and development enterprise; (ii) the Company has further improved its capacity and scheduled its projects properly, in order

to further improve its capacity utilization rate, ensuring smooth delivery of the orders on hand; the scale of scientific research and technical team has expanded with the addition of more mature technical personnel, providing strong guarantee for performance growth; (iii) the Company has further allocated its resources and continued to facilitate and strengthen its work in the supply sessions of the upstream industry chain, so as to guarantee and enhance the continuous service capability of the Company; (iv) the Company's capital management causes positive impact on overall performance.

- (II) Impact of non-operating profit or loss. It was mainly due to various factors such as government subsidies, gains on financial assets held for trading and acquisition of negative goodwill. The impact of non-recurring gains and losses on net profit after income tax was approximately RMB26.60 million, which is basically the same for the corresponding period of last year.

#### **IV. RISK WARNING**

There are no material uncertainties affecting the accuracy of the estimated results.

#### **V. OTHER EXPLANATION**

The financial data contained in this results estimate is prepared in accordance with the China Accounting Standards for Business Enterprises and the estimated data is only preliminary accounting figures. The specific and accurate financial data shall refer to the unaudited 2022 third quarterly results announcement and the 2022 Third Quarterly Report prepared in accordance with the China Accounting Standards for Business Enterprises or the International Financial Reporting Standards officially disclosed by the Company. Investors are advised to pay attention to investment risks.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Hong Kong, October 18, 2022

*As at the date of this announcement, the Board of the Company comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, Mr. Gu Xiaolei as a non-executive Director, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*